Close Menu

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals last week released data from a Phase II pilot study of its subcutaneously administered TTR-mediated amyloidosis (ATTR) drug revusiran, showing that the agent could knock down levels of its target protein by as much as 98.2 percent.

While treatment with revusiran, formerly known as ALN-TTRsc, was generally well tolerated, Alnylam disclosed that a number of patients in the open-label study experienced a variety of adverse events including one deemed serious.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.

Nov
13
Sponsored by
Agena Bioscience

This webinar will discuss advances in detecting MET and NTRK variants in tumor samples, which can help clinicians determine the appropriate therapy for cancer patients.